Model-based cost-effectiveness analyses for prostate cancer chemoprevention: A review and summary of challenges

PharmacoEconomics

Volumn 31, Issue 4, 2013, Pages 289-304

  Earnshaw, Stephanie R ^a   Brogan, Andrew P ^a   McDade, Cheryl L ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL PATHWAY; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DECISION MAKING; DRUG COST; DRUG WITHDRAWAL; EJACULATION DISORDER; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIFE EXPECTANCY; MEDLINE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW;

EID: 84876940949     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0037-6     Document Type: Review

References (46)

1. American Cancer Society. Cancer facts & figures. Atlanta: American Cancer Society; 2011. http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-029771.pdf. Accessed 10 Feb 2012.
2. National Cancer Institute. Cancer advances in focus: prostate cancer. Bethesda: NCI; 2011. http://www.cancer.gov/cancertopics/factsheet/cancer- advances-in-focus/prostate. Accessed 10 Oct 2011.
3. Crawford ED, Andriole GL, Marberger M, et al. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology. 2010;75(3):502-9.
4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-24. (Pubitemid 36859473)
5. Klein EA, Tangen CM, Goodman PJ, et al. Assessing benefit and risk in the prevention of prostate cancer: the Prostate Cancer Prevention Trial revisited. J Clin Oncol. 2005;23(30):7460-6. (Pubitemid 46291808)
6. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-202.
7. Merck & Co. Finasteride: Proscar [US prescribing information]. Whitehouse Station: Merck & Co.; 2012. http://www.merck.com/product/usa/pi- circulars/p/proscar/proscar-pi.pdf. Accessed 10 Feb 2012.
8. GlaxoSmithKline. Dutasteride: Avodart [US prescribing information]. Research Triangle Park: GlaxoSmithKline; 2011. http://us.gsk.com/products/ assets/us-avodart.pdf. Accessed 10 Feb 2012.
9. European Medicines Agency. Finasteride 5 mg tablets: summary of product characteristics; 2011. http://www.medicines.org.uk/EMC/medicine/23066/SPC/ Finasteride+5mg+Tablets/. Accessed 10 Feb 2012.
10. European Medicines Agency. Avodart (dutasteride) 0.5 mg soft capsules: summary of product characteristics. 2011. http://www.medicines.org.uk/EMC/ medicine/11618/SPC/Avodart+0.5mg+soft+capsules/. Accessed 10 Feb 2012.
11. Zeliadt SB, Etzioni RD, Penson DF, et al. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med. 2005;118(8):850-7. (Pubitemid 41097462)
12. Svatek RS, Lee JJ, Roehrborn CG, et al. The cost of prostate cancer chemoprevention: a decision analysis model [published erratum appears in Cancer Epidemiol Biomarkers Prev 2007 May 1;16(5):1042]. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1485-9. (Pubitemid 44299320)
13. Svatek RS, Lee JJ, Roehrborn CG, et al. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008;112(5):1058-65. (Pubitemid 351304590)
14. Earnshaw SR, McDade CL, Black LK, et al. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010;28(6):489-505.
15. Svatek RS, Lotan Y. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Cancer Prev Res (Phila). 2011;4(2):277-83.
16. Reed SD, Scales CD Jr, Stewart SB, et al. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. J Urol. 2011;185(3):841-7.
17. Kattan MW, Earnshaw SR, McDade CL, et al. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011;9(5):305-15.
18. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value Health. 2003;6(1):9-17. (Pubitemid 36228345)
19. Konski A, Watkins-Bruner D, Brereton H, et al. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer. 2006;106(1):51-7. (Pubitemid 43032548)
20. Penson DF, Ramsey S, Veenstra D, et al. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol. 2005;174(2):547-52 (discussion 52). (Pubitemid 40981597)
21. Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004;171(4):1537-42. (Pubitemid 38365413)
22. Tanvetyanon T. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2005;97(1):70-1.
23. Ito K, Elkin EB, Girotra M, et al. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med. 2010;152(10):621-9.
24. Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 2011;108(6):806-13.
25. Unger JM, LeBlanc M, Thompson IM, et al. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urol Oncol. 2004;22(4):362-8. (Pubitemid 38993318)
26. Zeliadt SB, Ramsey SD. Cost-effectiveness of prostate cancer chemoprevention among high-risk men. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):505-8.
27. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): prostate cancer. Fort Washington: NCCN; 2011. http://guidelines.nccn.org/published-guideline/0E460A39-A272-4B7A-D97E- DDB246FFC11F/guideline.pdf. Accessed 17 Feb 2012.
28. Schröeder FH, Roobol MJ, Andriole GL, et al. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol. 2009;181(1):69-74.
29. Schröeder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
30. Schröeder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2003;92(Suppl. 2):1-13. (Pubitemid 38091131)
31. Xu J, Sun J, Kader AK, et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate. 2009;69(14):1565-72.
32. Wilt TJ, Macdonald R, Hagerty K, et al. 5-alpha-reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int. 2010;106(10):1444-51.
33. Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008;1(3):174-81.
34. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43(4):347-55. (Pubitemid 40515624)
35. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41(1):153-64.
36. Ackerman SJ, Rein AL, Blute M, et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I, methods. Urology. 2000;56(6):972-80.
37. Bremner KE, Chong CA, Tomlinson G, et al. A review and meta-analysis of prostate cancer utilities. Med Decis Making. 2007;27(3):288-98. (Pubitemid 46801746)
38. Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15(4):369-76. (Pubitemid 29190028)
39. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
40. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices - budget impact analysis. Value Health. 2007;10(5):336-47. (Pubitemid 47481105)
41. Nuijten MJ. The selection of data sources for use in modelling studies. Pharmacoeconomics. 1998;13(3):305-16. (Pubitemid 28123370)
42. Nuijten MJ, Starzewski J. Applications of modelling studies. Pharmacoeconomics. 1998;13(3):289-91. (Pubitemid 28123368)
43. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics. 2000;17(5):501-13. (Pubitemid 30398807)
44. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics. 2000;17(5):461-77. (Pubitemid 30398805)
45. Sonnenberg FA, Roberts MS, Tsevat J, et al. Toward a peer review process for medical decision analysis models. Med Care. 1994;32(7 Suppl.):JS52-64.
46. Mandelblatt JS, Fryback DG, Weinstein MC, et al. Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med. 1997;12(9):551-8. (Pubitemid 27383039)